Need the Support of The Government to Reach The Last Mile: Dr Davinder Gill
On completion of 10 years in the field of vaccines and R&D, BW Healthcareworld got into a conversation with Dr Davinder Gill, CEO Hilleman Laboratories.
Dr Davinder Gill, CEO, Hilleman Laboratories
Describing their journey in the field of Research & Development for vaccines and vaccination, Dr Davinder Gill says, “The journey has been quite exciting. 10 years ago, we started as a startup organisation to address the needs of the vaccine’s R&D in countries like India.”
Hilleman Laboratories embarked on a strategy with the initial approach to try and address the needs of the problems that exist in children less than five in developing countries. And more specifically, they looked at enteric and diarrheal diseases, which are very prevalent in developing countries, also, the cause of a large number of mortality and morbidity rates. And they began to develop vaccines to research & development in this area.
“Over the course of time, we built a portfolio of products to address this need in the area of diarrhoea. And we are very fortunate that over the last 10 years we've managed to advance some of our vaccine candidates. And while they're still in the final stages of clinical development, we have been able to move from a very concept-based stage to finally a product stage,” adds Dr Gill.
Last decade in Research & Development
Dr Gill says, “First and foremost we have fully equipped R & D operations here in New Delhi. We have recruited a top-quality organization, staffing not only on the R & D side but also on the business side and the support side. And then the strategy and a key element of our journey was collaborations and cooperation across stakeholders in India and outside. Our approach in diarrheal diseases, we really had to forge important collaborations and alliances and we did that with organizations in India such as the Indian Council of Medical Research (ICMR) New Delhi and National Institute of Cholera and Enteric Disease (NICET) Kolkata, and also outside India with the Gotavax AB-Sweden, and others, as well as some clinical trial partnerships that be developed in Bangladesh. Our journey really covered a wide spectrum of organizational advancements, portfolio advancements as well as advancements on cooperation and collaboration in India and outside.”
Research & Development is another term for evolution in science. Upon asking him, what has been evolved in the field of medical sciences in the last 10 years? He answered, “There has been a lot of changes in the last 10 years. I'll begin by pointing out the renewed emphasis that we see on healthcare and health-related initiatives. funding on behalf of the Indian government.
In the last two to three years with programmes like the universal health coverage, increase boosts towards vaccines and vaccinations government has pushed the health sector towards progress. In addition to that, the regulatory environment has changed with the help of removal of bottlenecks we had, policies have been opened up and also the agencies have become much more approachable in terms of, discussions and dialogues. On the vaccine front, India as a country has made huge advances and we continue to be the dominant supplier of low-cost vaccines to the world.”
He added, “We saw the launch of the first indigenous vaccine Rotavac in India. Hilleman was also very privileged that we actually could do some work in the area of heat-stable, rotavirus vaccine. And at the global level, the increased emphasis on vaccines and vaccinations, even in terms of their approach systems, we have seen an improvement in that as well.
Heat Stable Vaccine
Diarrhoea is a major issue in the developing countries and Hilleman laboratories take proud in focusing on diarrheal children. It kills approximately half a million children around the world. In India alone, there are 200,000 deaths, because of diarrhoea in small children. Rotavirus, Cholera, are the pathogens for this fatal infection.
We chose to address this area, which is an unmet need. Coming forward with a novel formulation of heat-stable rotavirus at Hilleman Laboratories and later, Bharat biotech in collaboration with the ICMR and NICET helped in the further clinical testing stages. Shigella vaccine and other conjugate vaccines are some of our other R&D results. This class of vaccine tends to be very complex and countries like India need the capacity and the capability you work on things conjugate.
Globally, the vaccine industry is expanding anywhere from $40 to $50 billion USD. The Indian share in this industry is interesting. If you look at the supply of vaccines on the dose and the number of dose bases, India is the biggest manufacturer and supplier of vaccine doses around the world. But if you look at our market shares aren't very high because what we supply are affordable vaccines. What that means is that there's a lot of potential for India. The increased emphasis that the Indian government has given them on universal health care coupled with the fact that there is a renewed focus on vaccines and vaccination. A wide range of innovative vaccines like rotavirus vaccine, pneumococcal conjugate vaccine, and even the HPV vaccine for cervical cancer is now part of various immunization programs.
The need of the Country
Most importantly, the government needs to keep supporting vaccines, innovation and the energy behind it. They need to empower various stakeholders by to simplifying and incentivizing R & D.
Lately, there has been an observance of vaccine hesitation that the upper-middle-class people, who have never experienced these kinds of diseases are now starting to become a little hesitant. We need the support of the government and various stakeholders in order to address those needs. Otherwise, I think we'll end up in the situation opposite to what we are trying to create.
With such a geographical spread out and heterogeneous populations, we need to reach the last mile to vaccinate every child, irrespective of their exposure to these vaccines, otherwise in any vaccination program, you find that the children that are easy to reach get vaccinated, but those children that are hard to reach never get vaccinated. We need to put emphasis on systems and processes that allow us to address the gap.
At Hilleman labs, we have embarked upon the R&D such as our heat stable formulation, simple delivery device, called a vaccination pack. These are the innovations that address the types of needs. More recently, we also looking at needle-free injection with the use of microarray patches. As R & D organization, we are doing what we can, but I think we also need the support of the government in order to address this gap of what we call ‘the last mile reach’.